Via Reuters: EXCLUSIVE-Canada to donate its own Ebola vaccine to WHO for use in Africa. Excerpt: Canada will donate a small quantity of an experimental Ebola vaccine developed in its government lab to the World Health Organization for use in...
Via The Globe and Mail: U.S. sends experimental Canadian Ebola vaccine to trial. Regulators in the United States have officially granted permission for the first human clinical trial of Canadas experimental Ebola vaccine, a step that comes as experts from...
Ebola hemorrhagic fever (EHF), also referred as Ebola virus disease causes serious illness, which sometimes results into fatality if untreated. The vaccine that are used to treat Ebola virus disease are referred as Ebola vaccine. After the Ebola virus infection/attack human body shows symptoms - high fever, sore thr...
Mercks Ervebo V920 (VSV-EBOV) is a recombinant, replication-competent Ebola vaccine, consisting of a vesicular stomatitis virus (VSV), which has been genetically engineered to express a glycoprotein from the Zaire ebolavirus so as to provoke a neutralizing immune response to the Ebola virus.
The media is in a tizzy over the recent trial results of Mercks experimental Ebola vaccine, rVSV-ZEBOV (recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus).
AMES, IA--(Marketwired - Sep 4, 2014) - NewLink Genetics Corporation (NASDAQ: NLNK) today announced that the United States Food and Drug Administration (FDA) has given permission for the Company to proceed to Phase 1 clinical trials with their Ebola vaccine candidate. This vaccine was initially developed by the Public Health...
With talk turning to the idea that Ebola vaccines and drugs may be needed to quell the West African outbreak, the tiny U.S. company that holds the licence for a Canadian-made vaccine says it is working as fast as it can to get that option tested and ready for use.
Gavis announcement that it will finance the establishment of an emergency stockpile of 500,000 doses of Ebola vaccine is a positive step. MSF calls for a thorough, independent, and transparent estimate of the costs of manufacturing the vaccine, to ensure that the price paid is fair and reasonable.
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.
The results of a recent Phase IB study show that the novel Ebola vaccine, V920, was well-tolerated and “stimulated a rapid onset of binding and neutralizing antibodies,” which persisted for up to 1 year.
Washington: An experimental Ebola vaccine has been shown to effectively protect monkeys against the often-deadly virus, according to a study published today. The new medicine, described in the journal Science, is what is known as a whole virus
A genetically engineered Ebola vaccine was safe and induced a significant immune response in multiple phase 1 trials, researchers reported.
An experimental Ebola vaccine to be deployed in an outbreak in Democratic Republic of Congo has conquered some major scientific hurdles in giving high protection, but it now faces extreme real-world tests including heat, humidity, language barriers and lack of roads.
From 29-30 September, WHO held an expert consultation to assess the status of work to test and eventually license two candidate Ebola vaccines. More than 70 experts, including many from affected and neighbouring countries in West Africa, attended the event.
(CNN) -- A highly anticipated test of an experimental Ebola vaccine will begin next week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly outbreak in West Africa. After an expedited review by the U.S.
Russias health minister said Monday that an Ebola vaccine developed by the country over the last 15 months had shown encouraging results and would undergo further testing in West Africa.
The European Medicines Agency has recommended that the worlds first Ebola vaccine be approved, after its use in hundreds of thousands of people in Africa
Democratic Republic of Congo will start using Ebola vaccine as early as next week to counter a flare-up the heavily populated eastern part of the Central African country, health minister Oly Ilunga Kalenga said.
Pharma giant Merck has entered into an agreement with NewLink to develop the investigational Ebola vaccine, designed by scientists at Canadas National Microbiology Laboratory in Winnipeg.
a href="http://www.uni-protokolle.de/nachrichten/id/286681/",Scientists at the University of T bingen test Canadian Ebola vaccine ,/a, ...
A recap of Tuesdays top stories: Pneumonia number one killer of children; Australias wildfires rage on; Ebola vaccine gets green light; new child labour and trafficking study; Malnutrition soars in Latin America and Caribbean; Intellectual Property chief encourages innovation.
A trial of a vaccine against two known Ebola species can protect monkeys against a new strain that was identified in 2007, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) reported in Public Library of Science (PLoS) Pathogens. The study involved a vaccine already in development at NIAID that consists of prime and boost components. The prime is a DNA vaccine that contains DNA material from surface proteins of Zaire and Sudan Ebola viruses, and the boost is a weakened cold virus that delivers Zaire ebola virus surface protein. In earlier trials, the vaccine provoked a strong antibody response as well as a robust T-cell reaction in monkeys. In the latest trial, four macaque monkeys received the DNA prime, then a year later received the boost. Shortly thereafter, researchers exposed the four monkeys and four controls to lethal doses of Bundibugyo Ebola virus. The four unvaccinated monkeys got sick and three died, but the vaccinated ones showed no signs of illness. ...
See also. http://www.google.com/patents/CA2741523A1. See also. CA2741523A1, EP2350270A2, EP2350270A4, US20120251502, WO2010048615A3,. Astonishingly, the patent request filed by the U.S. government pertains to all variants of Ebola which share 70% or more of the protein sequences described in the patent: "[CLAIMS] …a nucleotide sequence of at least 70%-99% identity to the SEQ ID…". Furthermore, the patent request also seeks ownership over any and all Ebola viruses which are "weakened" or "killed," meaning the United States government is literally claiming ownership over all Ebola vaccines.. What this means, of course, is that the U.S. government could demand royalties on all Ebola vaccines.. Even more Orwellian is the fact that the U.S. government could use this patent to halt all other research for treatments or cures for Ebola.. Patent monopoly would give the U.S. government legal right to block all non-vaccine Ebola treatments, cures or research. Do you remember the massive medical ...
Ebola Virus Net is the web resource for anyone interested in ebola. The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.
Recent scientific research studies confirm the potential of turmeric curcumin as a vaccine for Ebola virus disease. A review of the studies was published in the International Journal of Experimental and Clinical Pathophysiology and Drug Research in February 2015.. The outbreak of Ebola in several neighboring countries in West Africa is fueling fears the virus could spread across continents. The apprehension is a bleak reminder of how epidemics in the past decimated populations in Europe and thought to have annihilated entire civilizations in the ancient world. The World Health Organization (WHO) reveals that the Ebola virus disease is progressing faster than efforts to contain it. Director General Margaret Chan says the organization is facing unprecedented challenges.. Turmeric curcumin ranks among the top herbal strategies for use in Ebola patients owing to its antioxidant and anti-inflammatory properties affirmed in more than 3,000 studies. The compound is credited with positive results on ...
Search the ASPR TRACIE Resource Library and view tailored Topic Collections comprised of current healthcare system preparedness resources.
Texas health-care worker tests positive for Ebola. An image from the U.S. Centres for Disease Control shows an Ebola Virus.. Phase one of the trials will focus on determining the proper dosage and any possible side effects of the vaccine.. Twenty vials of the vaccine have been sent to the Walter Reed Army Institute of Research in Maryland for testing on about 40 healthy volunteers, she said.. The announcement comes after a health worker in Texas became the first person to be infected with Ebola inside the United States. The nurse contracted it from a patient, a Liberian man who developed symptoms shortly after arriving in U.S.. American health officials say a breach of infection protocol led to the nurse catching the disease.. The Winnipeg Regional Health Authority has ordered additional supplies as part of their ongoing preparations for a possible Ebola diagnosis here.. When asked if the WRHA is concerned about the infection of Texas health worker, a spokesperson said the agency has sent ...
The second, rVSV-ZEBOV, was developed by the Public Health Agency of Canada in Winnipeg. The license for commercialization of the Canadian vaccine is held by an American company, NewLink Genetics, located in Ames, Iowa. The vaccine uses an attenuated or weakened vesicular stomatitis virus, a pathogen found in livestock, replacing one of its genes with an Ebola virus gene.. WHO reported two phase 1 trials of the cAd3-ZEBOV started in September in the U.S. and the U.K., and the first phase 1 trial of VSV-ZEBOV is due to start in early October in the U.S.. Get the bestselling landmark account of the first emergence of the Ebola virus, Richard Prestons No. 1 New York Times bestseller, "The Hot Zone." WHO further reported the government of Canada has donated 800 vials of rVSV-ZEBOV to WHO, a donation expected to translate into some 1,500 to 2,000 doses of the vaccine for use in Phase 1 trials.. Both companies told WHO that despite their dedication to augment current manufacturing capacity, ...
New study shows that an experimental vaccine uses antibodies to help protect nonhuman animals against the deadly Ebola virus infection. Ebola hemorrhagic
According to a release available to the Ghana News Agency the trial was led by the World Health Organisation (WHO), together with Guineas Ministry of Health, Medecins sans Frontieres and the Norwegian Institute of Public Health, in collaboration with other international partners.. Dr Marie-Paule Kieny, WHOs Assistant Director for Health Systems and Innovation, and the studys lead author said "While these compelling results come too late for those who lost their lives during West Africas Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenseless.". The vaccines manufacturer, Merck, Sharpe & Dohme, has received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted.. Since Ebola virus was first identified in 1976, sporadic outbreaks have been reported in Africa but the 2013-2016 West African outbreak, which ...
The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11,841 people in Guinea during 2015. Among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine.. The trial was led by the World Health Organization, together with Guineas Ministry of Health, Medecins sans Frontieres and the Norwegian Institute of Public Health, in collaboration with other international partners.. "While these compelling results come too late for those who lost their lives during West Africas Ebola epidemic, they show that when the next Ebola outbreak hits, we will not be defenceless," said Dr Marie-Paule Kieny, WHOs Assistant Director-General for Health Systems and Innovation, and the studys lead author.. The vaccines manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug ...
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue development of the Ebola vaccine; whether Vical or others will evaluate potential additional applications of the companys technology; whether the Ebola vaccine or any other product candidates will be shown to be safe and effective; whether the companys processes will result in rapid development and manufacturing of vaccines; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether the Animal Rule will be applicable to DNA-based products and whether it will provide a favorable regulatory pathway; whether Vical or its collaborative partners will succeed in marketing any product candidates; whether any funding under Project BioShield will be directed to the Ebola DNA vaccine; and ...
In this report, the Asia-Pacific Ebola Virus Vaccine market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,
Global Ebola Virus Vaccine Market Professional Survey Report 2017 Size and Share Published in 2017-06-14 Available for US$ 3500 at Researchmoz.us
Jackson Otim Oyugi is a soft spoken and multi-talented gentleman. He is also is a first cousin to Dr. Mathew Lukwiya, the first medical officer to die in the line of duty during Ugandas first Ebola outbreak in Gulu district in August, 2000. Jackson is participating in the first phase I Ebola/Marburg vaccine clinical trial on the African continent. The Makerere University Walter Reed Project (MUWRP) in Uganda is conducting the vaccine trial.
Two experimental DNA vaccines to prevent Ebola virus and the closely related Marburg virus are safe, and generated a similar immune response in healthy Ugandan adults as reported in healthy US adults earlier this year. The findings, from the first trial of filovirus vaccines in Africa, are published in The Lancet.
Just the word Ebola can send shivers down the spine. And no wonder. Ebola is one of the deadliest viruses around, and there aren't any approved
When people look back on 2014, it may be best remembered as the year of Ebola. Two previous assumptions - that the virus was confined to remote regions of central Africa, and that the notorious virulence of the disease acted as a kind of self-limiting factor, with epidemics always burning themselves out after their initial flare-up - were shattered. Since its discovery in 1976, Ebola has been a curiosity in virologys chamber of horrors, but in 2014 it well and truly arrived as a serious player in the global disease-threat league table. News on NewsHub.org
When Ebola erupted in West Africa a few years ago, it was catastrophic. But one good thing emerged from the outbreak: The development of an Ebola vaccine--
Soligenix entered in collaboration with the University of Hawaii and Hawaii Biotech is developing a heat stable subunit Ebola vaccine that does not require cold
One out of six Americans, 50 million total, enter a school on a daily basis. Mandatory vaccines are going to begin in schools and then the requirement will be expanded to daycare employees and healthcare workers. Right now, required vaccines are a part of the 2014 State legislative agenda across the country. I was told that an executive order will expand all mandatory vaccine requirements to include Ebola, TB , HIV and about two dozen, in total, vaccines.. In the 12 hours I have had to process this information, I have found solid confirmation of what I was told by my sources.. "Some proposed legislation this year goes so far as to require schools to provide vaccine education programs for children and parents, which is effectively turning our schools into marketing departments for vaccine manufacturers. AL SB 75 (Alabama) and NY A 3703/S 2070 (New York) would require schools to provide meningococcal vaccine education/promotion, while GA HB 162 requires schools in Georgia to educate the parents of ...
In an experiment, 4 monkeys received the vaccine, later survived a lethal dose of Ebola virus; 2 other animals that did not receive the vaccine died within a week
Washington: An experimental vaccine to prevent Ebola virus disease has been found to be well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial, researchers report.
Twenty healthy volunteers will next week enter a 48-week trial for a US-developed vaccine against the deadly Ebola virus. The trial has been moved forward due to the current outbreak, but the first results are unlikely before the year end.
A healthy Briton has today become the first volunteer to receive a potentially life-saving new vaccine to tackle the Ebola virus spreading through West Africa.
Researchers at the National Institutes of Health are accelerating human clinical trials for what scientists hope is a promising new vaccine to combat the deadly Ebola virus. Phase 1 of the clinical trials, which were previously not expected to begin until the end of September, will start early...
The Ebola virus is one of the most dangerous and feared pathogens on the planet for which there is no effective treatment, but at least three companies are poised to make significant developments towards one in the near future.
In a small trial, an experimental vaccine protected 100 percent of people at high risk for Ebola. But more data are needed to figure out exactly how well the vaccine works.
Two experimental vaccines against Ebola are currently being tested for safety, and health officials have said that millions of doses could be available by the end of next year. But how do the vaccines work?
The world has been warned that the current Ebola epidemic may not end without the use of a vaccine - and no licensed vaccines exist yet. That may soon change, because scientists are making swift progress…